3Dossett LA, Redhage LA, Sawyer RG, et al. Revisiting the validity of APACHE II in the trauma tCU: improved risk stratification in crit- ically injured adults[J]. Injury, 2009, 40(9):993-998.
4Samir M. Fakhry, Brad Martin, Hasan A1 Harakeh, et al. Proportional Costs in Trauma and Acute Care Surgery Patients: Dominant Role of Intensive Care Unit Costs[J]. Journal of the American College of Sur- geons,2013, 216(4):607-614.
5KBent J, Hak E, Hoes AW, et al. A prediction rule for elderly primary- care patients with lower respiratory tract infections[J].Eur Respir J, 2007, 29(5):969-975.
6Garc i a-V C1 zquez E, Soto S, G 6 mez J, et al. Simple criteria to as- sess mortality in patients with community-acquired pneu- monia[J]. Med Clin(Barc), 2008,131(6):201-204.
7Huang J, Tang Y Q, Sun J Y. Intravenous colistin sulfate:Ararely used form of polymyxin E for the treatment of severe multi-drug-re- sistantGram-negative bacterial infections[J]. Scandinavian Journal of Infectious Diseases, 2010, 42(4):260-265.
8Espa h a PP, Capelastegui A, Gorordo I, et al. Development and val- idation of a clinical prediction rule for severe community-acquired pneumonia[J]. Am J Respir Crit Care Med, 2006, 174(11):1249- 1256.
9Ruiz-Gonzlez A, Falguera M, Vires M, etal. community-acquired pneumonia:development of a bedside predictive model and scoring system to identify the aetiology[J]. Respir Med, 2000, 94(5):505-510.
